Reported Earlier, Evie Ring's Pulse Oximeter Exceeds FDA Accuracy Guidelines In Movano Health's Second Hypoxia Trial
Portfolio Pulse from Benzinga Newsdesk
Movano Health's Evie Ring, a consumer wellness device, has exceeded FDA accuracy guidelines in its second hypoxia trial, achieving a root mean square error average of 2.46% against the FDA guidance of 3.5% for SpO2. The trial used the commercial production model of the Evie Ring, which will be submitted to the FDA and sold under the brand name Evie Med. The device outperformed two hospital-grade reference pulse oximeters in the study.
March 15, 2024 | 6:28 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Movano Health's Evie Ring has outperformed FDA accuracy guidelines in a hypoxia trial, indicating strong potential for FDA approval and commercial success.
The successful trial results of the Evie Ring not only demonstrate its superior accuracy over existing hospital-grade pulse oximeters but also indicate a strong potential for FDA approval. This could significantly boost investor confidence in Movano Health, potentially leading to an increase in stock price in the short term as the market reacts to the positive news.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100